IC
CUE icon

Ikarian Capital’s Cue Biopharma CUE Stock Holding History

Ikarian Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.29M Buy
+104,364
New +$2.36M 0.35% 70

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Ikarian Capital's CUE Position: Q2 2026 in Review

Ikarian Capital opened a new position in Cue Biopharma (CUE) in Q2 2026: 104,364 shares worth $3.29M. The stake represents 0.35% of the portfolio and ranks #70 among its holdings.

46 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Ikarian Capital held 104,364 shares of Cue Biopharma worth $3.29M as of Q2 2026.
  • Cue Biopharma was a new Ikarian Capital position in Q2 2026.
  • Cue Biopharma made up 0.35% of Ikarian Capital's portfolio in Q2 2026, its #70 holding.
  • 46 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.